Figure 2
From: Promising SARS-CoV-2 main protease inhibitor ligand-binding modes evaluated using LB-PaCS-MD/FMO
(A) Cell-based and SARS-CoV-2 Mpro inhibition screening; (B,C) effect of rubraxanthone on cell viability, as determined using MTS assay; and (D) Lineweaver–Burk plot of rubraxanthone-induced SARS-CoV-2 Mpro inhibition.
